PAM
RXDX

Panagora Asset Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Panagora Asset Management’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-245
Closed -$6K – 2546
2021
Q2 		$6K Buy
+245
New +$5.46K ﹤0.01% 2461

Other funds holding RXDX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Panagora Asset Management's RXDX Position: Q3 2021 in Review

Panagora Asset Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q3 2021, closing a stake of 245 shares — an estimated $6K sold.

Panagora Asset Management first reported a position in RXDX in Q2 2021 and held it in 1 quarter. The position peaked at $6K in Q2 2021. 51 funds tracked by Wall St. Rank hold RXDX as of Q3 2021.

  • Panagora Asset Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Panagora Asset Management sold 245 Prometheus Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $6K.
  • Panagora Asset Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Panagora Asset Management's Prometheus Biosciences, Inc. Common Stock position peaked at $6K in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q3 2021.

Based on Panagora Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.